Hormone Therapy in Prostate Cancer

Wingo P.A. , Tong T. , Bolden S. : Cancer Statistics. CA Cancer J Clin, 45: 8–30, 1995.

Garnick M.B. , Fair W. : Combating prostate cancer. Sci Am, 279: 74–83, 1998.

Huggins C. , Hodges C.V. : Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res, 1: 293–297, 1941.

Blackard C.E. , Doe R.P. , Mellinger G.T. : Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer, 26: 249, 1970.

Benson R.C. Jr. , Gill G.M. : Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer. Am J Clin Oncol, 9: 341, 1986.

Kim J.H. , Khil M.S. , Kim S.H. : Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer. Int J Radiat Oncol Biol Phys, 29: 555, 1994.

Schally A.V. , Arimura A. , Baba Y. : Isolation and properties of the FSH and LH realising hormone. Biochem Biophys Res Commun, 43: 393–399, 1971,

McConnell J.D. : Physiologic basis of endocrine therapy for prostatic cancer. Urol Clin North Am, 18: 1, 1991.

Pantelides M.L. , Bowman S.P. , George N.J. : Levels of prostate specific antigen that predict skeletal spread in prostate cancer, Br J Urol, 70: 299, 1992.

Soloway M.S. , Chodak G. , Vogelzang N.J. : Zoladex versus orchiectomy in tratment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. Urology, 37: 46, 1991.

Waxman J. , Man A. , Hendry W.F. : Importance of early tumor exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed), 291: 1387, 1985.

Thompson I.M. , Zeidman E.J. , Rodriguez F.R. : Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol, 144: 1479, 1990.

Cook T. , Sheridan W.P. : Development of GnRH antagonists for prostate cancer: new approaches to treatment. The Oncologist, 5: 162–168, 2000.

de Voogt H.I. , Smith P.H. , Pavone-Macaluso M. , de Pauw M. , Suciu S. : Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol, 135: 303–307, 1986.

Thompson I.M. , Zeidman E.J. , Rodriguez F.R. : Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. [see comments]. J Urol, 144: 1479–1480, 1990.

Sogani P.C. , Vagaiwala M.R. , Whitmore W.F. : Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer, 54: 744–750, 1984.

McLeod D.G. , Kolvenbag G.J. : Defining the role of antiandrogens in the treatment of prostate cancer. [Review] Urology, 47(Suppl 1A): 85–89; 1996.

Araonson N. , Seidenfeld J. , Samson D.J. : Relative effectiveness and cost-effectiveness of methods and androgen suppression in the treatment of advanced prostate cancer. Evidence based report/technology assessment number 4. Prepared by Blue Cross/Blue Shield Association Evidence Based practice center under contract number 290-97-0015. AHCPR Publication number 99-E0012. Rockville, MD: Agency for Health Care Policy and Research, 1999

Prostate Cancer Trialists’ Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet, 355: 1491, 2000.

Arai Y. , Yoshiki T. , Yoshida O. : Prognostic significance of prostate specific antigen in endocrine treatment for prostate cancer

Sharifi R. : Casodex versus castration in treatment of stage D2 prostate cancer: prostate specific antigen (PSA) as a measure of outcome. Proc Amer Soc Clin Oncol, 12: 241, 1993.

See W A M.D. , McLeod D. M.D. , Iversen P. M.D. , Wirth M.D. : The bicalutamide early prostate cancer program: Demography. Urol Oncol, 6: 43–47, 2001.

Rennie P.S. , Bruchovsky N. , Coldman A.J. : Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J Steroid Biochem Mol Biol, 37: 843, 1990.

Byar D.P. , Corle D.K. : Hormone therapy for prostate cancer: results of the Veteran Administration Cooperative Urological Research Group studies. NCI Monogr, 7: 165, 1988.

MRC Protstate Cancer Working Party Investigator Group. BJU, 79: 235–246, 1997.

Schroder F.H. : Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. [Review]. BJU Int, 83: 161–170, 1999.